ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Interferon-gamma Responses to HCMV Infection in HIV Positive Individuals

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00168259
Recruitment Status : Completed
First Posted : September 15, 2005
Last Update Posted : January 20, 2012
Sponsor:
Collaborator:
Cellestis
Information provided by (Responsible Party):
Jennifer Hoy, The Alfred

Brief Summary:
The study is designed to evaluate interferon responses to CMV in HIV positive individuals and a component will look at interferon responses to CMV in HIV positive individuals over time after commencement of antiretroviral therapy. We will also look at the correlation between CD4 T cell numbers and HLA type with the interferon response.

Condition or disease
HIV Infection CMV Infection

Study Type : Observational
Actual Enrollment : 20 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Evaluation of Interferon-gamma Responses to HCMV Infection in HIV Positive Individuals
Study Start Date : December 2004
Actual Study Completion Date : December 2009

Resource links provided by the National Library of Medicine

Drug Information available for: Interferon
U.S. FDA Resources




Biospecimen Retention:   Samples With DNA
Plasma, and DNA


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
HIV infected patients with past CMV infection initiating antiretroviral therapy
Criteria

Inclusion Criteria:

  1. HIV positive with history of documented HCV infection
  2. Over 18 years old
  3. HIV positive
  4. Antiretroviral naive, starting on antiretroviral therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00168259


Locations
Australia, Victoria
Alfred Hospital
Melbourne, Victoria, Australia, 3004
Sponsors and Collaborators
The Alfred
Cellestis
Investigators
Principal Investigator: Sharon Lewin, Professor The Alfred

Responsible Party: Jennifer Hoy, Professor Jennifer Hoy, The Alfred
ClinicalTrials.gov Identifier: NCT00168259     History of Changes
Other Study ID Numbers: 185/04
First Posted: September 15, 2005    Key Record Dates
Last Update Posted: January 20, 2012
Last Verified: January 2012

Keywords provided by Jennifer Hoy, The Alfred:
Treatment Naive
HIV

Additional relevant MeSH terms:
Infection
Communicable Diseases
HIV Infections
Cytomegalovirus Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Herpesviridae Infections
DNA Virus Infections
Interferons
Interferon-gamma
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents